102 related articles for article (PubMed ID: 16153770)
1. In vitro metabolic studies on the selective metabotropic glutamate receptor sub-type 5 (mGluR5) antagonist 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl]-pyridine (MTEP).
Green MD; Yang X; Cramer M; King CD
Neurosci Lett; 2006 Jan; 391(3):91-5. PubMed ID: 16153770
[TBL] [Abstract][Full Text] [Related]
2. The metabotropic glutamate 5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine reduces ethanol self-administration in multiple strains of alcohol-preferring rats and regulates olfactory glutamatergic systems.
Cowen MS; Djouma E; Lawrence AJ
J Pharmacol Exp Ther; 2005 Nov; 315(2):590-600. PubMed ID: 16014750
[TBL] [Abstract][Full Text] [Related]
3. In vitro microsomal metabolic studies on a selective mGluR5 antagonist MTEP: characterization of in vitro metabolites and identification of a novel thiazole ring opening aldehyde metabolite.
Yang X; Chen W
Xenobiotica; 2005 Aug; 35(8):797-809. PubMed ID: 16278192
[TBL] [Abstract][Full Text] [Related]
4. MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats.
Ossowska K; Konieczny J; Wolfarth S; Pilc A
Neuropharmacology; 2005 Sep; 49(4):447-55. PubMed ID: 15919101
[TBL] [Abstract][Full Text] [Related]
5. mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition.
Pietraszek M; Gravius A; Schäfer D; Weil T; Trifanova D; Danysz W
Neuropharmacology; 2005 Jul; 49(1):73-85. PubMed ID: 15992582
[TBL] [Abstract][Full Text] [Related]
6. The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety.
Busse CS; Brodkin J; Tattersall D; Anderson JJ; Warren N; Tehrani L; Bristow LJ; Varney MA; Cosford ND
Neuropsychopharmacology; 2004 Nov; 29(11):1971-9. PubMed ID: 15305166
[TBL] [Abstract][Full Text] [Related]
7. [3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization.
Anderson JJ; Rao SP; Rowe B; Giracello DR; Holtz G; Chapman DF; Tehrani L; Bradbury MJ; Cosford ND; Varney MA
J Pharmacol Exp Ther; 2002 Dec; 303(3):1044-51. PubMed ID: 12438526
[TBL] [Abstract][Full Text] [Related]
8. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
[TBL] [Abstract][Full Text] [Related]
9. The role of group I metabotropic glutamate receptors in acquisition and expression of contextual and auditory fear conditioning in rats - a comparison.
Gravius A; Barberi C; Schäfer D; Schmidt WJ; Danysz W
Neuropharmacology; 2006 Dec; 51(7-8):1146-55. PubMed ID: 16905160
[TBL] [Abstract][Full Text] [Related]
10. Metabotropic glutamate receptor mGlu5 is a mediator of appetite and energy balance in rats and mice.
Bradbury MJ; Campbell U; Giracello D; Chapman D; King C; Tehrani L; Cosford ND; Anderson J; Varney MA; Strack AM
J Pharmacol Exp Ther; 2005 Apr; 313(1):395-402. PubMed ID: 15590770
[TBL] [Abstract][Full Text] [Related]
11. mGlu1 and mGlu5 receptor antagonists lack anticonvulsant efficacy in rodent models of difficult-to-treat partial epilepsy.
Löscher W; Dekundy A; Nagel J; Danysz W; Parsons CG; Potschka H
Neuropharmacology; 2006 Jun; 50(8):1006-15. PubMed ID: 16563443
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; search for cocaine medications.
Iso Y; Grajkowska E; Wroblewski JT; Davis J; Goeders NE; Johnson KM; Sanker S; Roth BL; Tueckmantel W; Kozikowski AP
J Med Chem; 2006 Feb; 49(3):1080-100. PubMed ID: 16451073
[TBL] [Abstract][Full Text] [Related]
13. Anxiolytic-like action of MTEP expressed in the conflict drinking Vogel test in rats is serotonin dependent.
Stachowicz K; Gołembiowska K; Sowa M; Nowak G; Chojnacka-Wójcik E; Pilc A
Neuropharmacology; 2007 Nov; 53(6):741-8. PubMed ID: 17870136
[TBL] [Abstract][Full Text] [Related]
14. 5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity.
Roppe JR; Wang B; Huang D; Tehrani L; Kamenecka T; Schweiger EJ; Anderson JJ; Brodkin J; Jiang X; Cramer M; Chung J; Reyes-Manalo G; Munoz B; Cosford ND
Bioorg Med Chem Lett; 2004 Aug; 14(15):3993-6. PubMed ID: 15225713
[TBL] [Abstract][Full Text] [Related]
15. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats.
Pietraszek M; Sukhanov I; Maciejak P; Szyndler J; Gravius A; Wisłowska A; Płaźnik A; Bespalov AY; Danysz W
Eur J Pharmacol; 2005 May; 514(1):25-34. PubMed ID: 15878321
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide].
Satow A; Maehara S; Ise S; Hikichi H; Fukushima M; Suzuki G; Kimura T; Tanak T; Ito S; Kawamoto H; Ohta H
J Pharmacol Exp Ther; 2008 Aug; 326(2):577-86. PubMed ID: 18487514
[TBL] [Abstract][Full Text] [Related]
17. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, radiolabeling, in vitro and in vivo evaluation of [18F]-FPECMO as a positron emission tomography radioligand for imaging the metabotropic glutamate receptor subtype 5.
Lucatelli C; Honer M; Salazar JF; Ross TL; Schubiger PA; Ametamey SM
Nucl Med Biol; 2009 Aug; 36(6):613-22. PubMed ID: 19647167
[TBL] [Abstract][Full Text] [Related]
19. Physical and crystallographic characterisation of the mGlu5 antagonist MTEP and its monohydrochloride.
McIldowie MJ; Gandy MN; Skelton BW; Brotchie JM; Koutsantonis GA; Spackman MA; Piggott MJ
J Pharm Sci; 2010 Jan; 99(1):234-45. PubMed ID: 19499574
[TBL] [Abstract][Full Text] [Related]
20. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
